The FLEX study is a randomized, blinded, and placebo-controlled study assessing the efficacy and safety of an investigational drug for adults diagnosed with Generalized Myasthenia Gravis (gGM). The injectable investigational drug is being evaluated over a 12-week induction period and a 12-week maintenance period. Based on completion of these periods and a participant's response to the investigational injection, participants may qualify to continue in a 52-week extension study of the investigational drug. If you choose to enter this study, you will participate in the study for up to approximately 84 weeks (1 ½ years) and you will be asked to attend up to 34 study visits; visits can last from 1 to 4 hours.

It is unknown at this time whether the study treatment will improve participant's health. The potential risks of this study include the possibility of infections, low albumin levels, and increases in blood cholesterol.

The purpose of this research study is to determine how well and safe deucravacitinib, an investigational/non-approved United States Food and Drug Administration (US FDA) medication, is in treating Systemic Lupus Erythematosus (SLE, lupus).

Participation in the study will involve being assigned deucravacitinib or a placebo (a drug that looks likes the study medication but does not contain any medication) and completing a series of in person clinic visits much like those completed as part of standard of care. Blood and urine samples will be collected for both routine health and safety tests as well as research/experimental testing.

The study will require 16 visits over a period of 14 months. There is an optional extension to the study possible, should you wish to continue and the study doctor feels that you remain a good candidate for participation. Study medication is provided and compensation is available for participation.

The purpose of this study is to determine if the investigational (not FDA approved) drug VIB4920 can be an effective treatment for patients with active Lupus Nephritis (LN).

This study will compare treatment with MMF (mycophenolate mofetil), Prednisone, plus the study medication VIB4920 to treatment with MMF and Prednisone alone.

Participants will have 16 scheduled visits that will involve routine monitoring of disease activity, up to two kidney biopsies, and blood and urine specimen collections. Participation in this study will last approximately 1 year and 2 months. Compensation is available for participation.

The purpose of this study is to create a de-identified, public use,
repository of data of Chronic Obstructive Pulmonary Disease (COPD)
patients with by Alpha-1 antitrypsin deficiency (AATD), a rare genetic
condition that can cause COPD and emphysema.

The purpose of this study is to see if nipocalimab is safe and useful for treating Adults with Generalized Myasthenia Gravis. Myasthenia gravis (MG) is a rare disease that affects the muscles and brain; causes tiredness and weakness in the eye muscles, arms, legs, and neck, and may cause difficulty with breathing. You must be diagnosed with myasthenia gravis to be in this study. Another purpose of this study is to find out how long nipocalimab stays in and acts on your body. This is measured by blood tests. Another purpose is to find out if nipocalimab can cause side effects, which are unexpected or unwanted reactions from taking a drug.

Participants will first be enrolled into the Double-Blind Placebo-Controlled Treatment Period which will last for about 24 weeks. Participants in this period of the study will receive either nipocalimab or a placebo through an infusion (IV). Participants with come for an office visit every 2 weeks to obtain the infusion, complete questionnaires, perform safety assessments and lab tests.

At the end of the Double-Blind treatment period, your study doctor will determine if you are eligible to enroll in the Open-Label Extension (OLE) period in which you would be able to receive nipocalimab infusions for approximately 2-5 years. There also may be a chance you did not participate in the Double-Blind Treatment Period of this study but can still enroll in the Open-Label Extension. Participants will complete the same activities in the OLE has the Double-Blind Placebo-Controlled Treatment Period.

The total amount of time the subject would be on the study is about 6 months for the Double-Blind Placebo-Controlled Treatment Period with an additional 2-5 years for the Open-Label Extension (OLE) period.

In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamcyin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.

The purpose of this study is to test whether a drug called PRA023/MK7240 (the study drug) is a good treatment for patients with Systemic Sclerosis associated with Interstitial Lung Disease (SSc-ILD). The study drug PRA023/7240 is an investigational drug that is given by infusion every 4 weeks. An investigational drug is not approved by The US Food and Drug Administration. It can only be used in a research study like this one. In this study, PRA023/MK7240 will be compared with a placebo (dummy drug). The placebo will be a saline solution that does not have any study drug in it. The comparison with the placebo helps to determine whether the effects seen in your body is because of the PRA023/MK7240 or not. This is a randomized study meaning that you will be assigned by chance (like flipping a coin) to receive either the study drug or placebo. This will be done with the help of a computer-based program and you will have 50% chance of receiving either the study drug or placebo. The study is double-blinded study and 50 weeks long, meaning you and your study doctor will not know what you are receiving, the study drug or placebo.

The study is sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. The study is being done at approximately 25 sites across the United States. The main portion of the study will require 15 visits to the MUSC main campus and will have the following procedures completed over the course of your participation: blood draw, physician-led assessments of your disease (for example physical exam and skin thickness testing), tests to assess your pulmonary function and health (Pulmonary Function Test (PFT) and High Resolution Computed Tomography (HRCT)), electrocardiogram, as well as asked to complete surveys. If you complete the initial blinded treatment period of 50 weeks, the study doctor will discuss whether you are eligible to enter the open label period of the study, meaning no placebo. If you are eligible and agree, you will receive 500 mg of study drug once every 4 weeks for an additional 52 weeks. Compensation is available for participation.

This observational, non-medication study's purpose is to help learn more about the immune system's inflammation process involved in lupus. The study will be enrolling both lupus and non-lupus (healthy control) females aged 18 and older who identify as Black/African American and Non-Hispanic or White and Non-Hispanic for this comparison study. Participation involves a one-time blood collection.

There are no direct benefits in participating, but it is hoped information learned may help us to develop a better understanding of lupus. Compensation is available for participation.

The purpose of this study is to test whether a drug called HZN-825 (the study drug) is an appropriate treatment for patients with Systemic Sclerosis (SSc). HZN-825 is an investigational drug that taken by mouth as a pill. An investigational drug is not approved by The US Food and Drug Administration and can only be used in a research study, like this one.

In this study, HZN-825 will be compared with a placebo (a pill that looks like the study pill but does not have any study drug in it). The comparison with the placebo helps to determine whether the effects seen in your body is because of HZN-825 or not. This is a randomized study meaning that you will be assigned by chance (like flipping a coin) to receive either the study drug or placebo. This will be done with the help of a computer-based program, and you will have 67% chance of receiving HZN-825. The study is double-blinded, meaning you and your study doctor will not know what you are receiving, the study drug or placebo. Should an emergency arise, and it is determined necessary, your study doctor will be able to find out what medication group you have been assigned.

The study is sponsored by Horizon Therapeutics Ireland DAC. The study is being done at approximately 135 sites across the world. The study is 60 weeks long will require 12 visits to the MUSC main campus. During study participation, the following procedures will be completed: blood draw, physician-led assessments of your disease (for example physical exam and skin thickness testing), tests to assess your pulmonary function and health (Pulmonary Function Test (PFT) and High-Resolution Computed Tomography (HRCT)), electrocardiogram, as well as being asked to complete surveys about your overall health and wellbeing.